BeOne Medicines AG's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Shows the company's financial performance and position during the first half of the year.
Reveals how much money the company made and spent in Q2, helping investors understand recent performance.
A large unexpected expense reduces future profits and shows regulatory risks in international operations.
Leadership changes and larger employee stock pools affect ownership structure and future decision-making.
A major drug approval opens a new revenue stream and validates the company's research and development.
Shows the company's financial performance and position during the first quarter of the year.
Reveals how much money the company made and spent in Q1, helping investors understand recent performance.
Stocky reads BeOne Medicines AG's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
BeOne Medicines AG's most recent tracked filing was a 10-Q on 5 Aug 2026: Files quarterly report for six months ending June 30, 2026.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.